Compare · BTI vs NAGE
BTI vs NAGE
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI is the larger of the two at $130.23B, about 485.2x NAGE ($268.4M).
- Over the past year, BTI is up 24.1% and NAGE is down 74.5% - BTI leads by 98.6 points.
- BTI has been more active in the news (9 items in the past 4 weeks vs 2 for NAGE).
- BTI has more recent analyst coverage (14 ratings vs 1 for NAGE).
PerformanceBTI+24.14%NAGE-74.50%
2025-06-09+0.00%2026-06-09
- Company
- British American Tobacco Industries p.l.c.
- Niagen Bioscience Inc.
- Price
- $59.43-0.45%
- $3.42+1.33%
- Market cap
- $130.23B
- $268.4M
- 1M return
- +1.94%
- -17.67%
- 1Y return
- +24.14%
- -74.50%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- News (4w)
- 9
- 2
- Recent ratings
- 14
- 1
BTI
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- Large owner Bt De Investments Inc. converted options into 95,281,277 shares and was granted 14,662,765 shares (SEC Form 4)
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest NAGE
- Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
- Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
- Niagen Bioscience Announces Participation in Upcoming Investor Conferences
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
- SEC Form DEFA14A filed by Niagen Bioscience Inc.
- SEC Form DEF 14A filed by Niagen Bioscience Inc.
- Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™